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Abstract
During pathological pain, the actions of the endocannabinoid system, including
the cannabinoid 2 receptor (CB2R), leads to effective anti-allodynia and modiﬁes a
varietyofspinalmicroglialandastrocyteresponses.Here,followingspinaladminis-
trationoftheCB 2Rcompound,AM1241,weexaminedimmunoreactivealterations
in markers for activated p38 mitogen-activated protein kinase, interleukin-1β (IL-
1β), the anti-inﬂammatory cytokine, interleukin-10 (IL-10) as well as degradative
endocannabinoid enzymes, and markers for altered glial responses in neuropathic
rats. In these studies, the dorsal horn of the spinal cord and dorsal root ganglia
were examined. AM1241 produced profound anti-allodynia with corresponding
immunoreactive levels of p38 mitogen-activated kinase, IL-1β, IL-10, the endo-
cannabinoid enzyme monoacylglycerol lipase, and astrocyte activation markers
that were similar to nonneuropathic controls. In contrast, spinal AM1241 did not
suppress the increased microglial responses observed in neuropathic rats. The dif-
ferencesinﬂuorescentmarkersweredeterminedwithindiscreteanatomicalregions
byapplyingspectralanalysismethods,whichvirtuallyeliminatednonspeciﬁcsignal
duringthequantiﬁcationofspeciﬁcimmunoﬂuorescentintensity.Thesedatareveal
expression proﬁles that support the actions of intrathecal AM1241 control patho-
logical pain through anti-inﬂammatory mechanisms by modulating critical glial
factors,andadditionallydecreaseexpressionlevelsofendocannabinoiddegradative
enzymes.
Introduction
Microglia and astrocytes (glia) play a crucial role in the de-
velopment and maintenance of chronic neuropathic pain in
variousanimalmodels(DeLeoetal.2007).Increasedglialac-
tivationiswellknowntooccurinthedorsalhornofthespinal
cord in animal models of peripheral neuropathy, as demon-
strated by increased production of glial ﬁbriliary acidic pro-
tein(GFAP)inastrocytesandionizedcalciumbindingadap-
tor molecule-1 (Iba-1) in microglia (Pekny and Pekna 2004;
Racz et al. 2008b). When strongly activated, glia can increase
expression of proinﬂammatory factors such as phosphory-
lated p38 mitogen-activated protein kinase (p-p38MAPK)
that can lead to production and release of proinﬂammatory
cytokines such as interleukin-1β (IL-1β)a n dt u m o rn e c r o -
sis factor-α (TNF-α), which subsequently bind and activate
their respective receptors on nearby neurons and glia (De
Leo et al. 2006; Watkins et al. 2007; Milligan and Watkins
2009). The cellular anatomical localization of p-p38MAPK
is predominantly expressed and is functionally important in
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spinalcordmicrogliaandcorrespondingsatellitecellsindor-
sal root ganglia (DRG) during neuropathic pain (Schafers
et al. 2003; Svensson et al. 2005b; Boyle et al. 2006; Ji and
Suter 2007; Sorkin et al. 2009). IL-1β mRNA and protein
are upregulated within spinal cord homogenates of rats with
pathological pain (Holguin et al. 2004). However, immuno-
histochemicaldetectionofincreasedIL-1β protein,aswellas
alterationsintheanti-inﬂammatorycytokine,interleukin-10
(IL-10), in intact spinal cord dorsal horn from rats with pe-
ripheralneuropathyhasnotyetbeencharacterized.Onegoal
ofthesestudiesistoquantifyimmunoreactivity(IR)forIL-1β
aswellasIL-10 insectionsoftheintactdorsalhornfromrats
with chronic peripheral neuropathy. In addition, changes in
immunoreactive p-p38MAPK levels were examined to verify
prior reports that increase in p-p38MAPK occurs in combi-
nation with increased proinﬂammatory cytokine expression.
Peripheral neuropathy is assessed by the presence of allody-
nia, characterized as a sensitivity to light mechanical touch
that is not present under healthy conditions.
AM1241isawidelycharacterizedcannabinoidagonistthat
controls hyperalgesia (exaggerated nociceptive thresholds)
and allodynia following intraperitoneal (i.p.) (Ibrahim et al.
2006; Rahn et al. 2008), intravenous (i.v.) (Beltramo et al.
2006), intra-DRG, or intrathecal (i.t.) (Hsieh et al. 2011) in-
jection. In the current studies, we sought to determine the
timecourse and dose-dependent changes in allodynia pro-
duced by unilateral chronic constriction injury (CCI) of
the rat sciatic nerve following i.t. AM1241 administration
to avoid known peripheral actions of the compound. The
development of bilateral allodynia following unilateral CCI
has been documented in numerous studies (Paulson et al.
2000, 2002; Milligan et al. 2006, 2007; Loram et al. 2009).
We therefore followed not only bilateral sensory behavioral
changes, but also quantitative changes in the bilateral IR of:
(1) cytokines, (2) p-p38MAPK, (3) enzymes responsible for
thebioavailabilityofendocannabinoidscharacterizedtoexert
analgesicproperties(Kinseyetal.2009,2010),and(4)mark-
ers reﬂecting changes in astrocytic and microglial responses
in spinal cord and DRG.
Existing evidence shows that AM1241 acts as an agonist
at the cannabinoid 2 receptor (CB2R) that results in sup-
pression of nociceptive responses (Rahn et al. 2010), and
prevents neuropathic and inﬂammatory pain (Nackley et al.
2004; Beltramo et al. 2006; Rahn et al. 2008), with selectivity
demonstrated not only by utilizing pharmacological CB2R
antagonists, but also by examining AM1241 analgesic efﬁ-
cacy in CB2R knockout mice (Ibrahim et al. 2003, 2006).
CB2Rs are characterized on microglia and macrophages in
cell culture (Walter et al. 2003; Cabral and Marciano–Cabral
2005; Ehrhart et al. 2005) and in the rodent spinal cord fol-
lowingperipheralnervedamage(Zhangetal.2003;Romero-
Sandoval et al. 2008a) or in transgenic mice overexpress-
ing the CB2R (Racz et al. 2008b), as well as in the human
central nervous system (CNS) under inﬂammatory diseased
conditions (Nunez et al. 2008). Given that AM1241 can act
on CB2Rs expressed on spinal microglia, the potential ad-
ditional (1) cytokine and (2) p-p38MAPK involvement in
AM1241sefﬁcacyinproducingspinalanti-inﬂammatoryac-
tions concurrent with anti-allodynia were examined in these
studies.
Related to these goals, we examined two methods to
analyze immunoﬂuorescent images of spinal cord tissue
sections to identify the most sensitive procedure for de-
tecting and quantifying differences in speciﬁc immunore-
activeproteinmarkers.Inthiscontext,analternativemethod
that utilizes spectral analysis procedures, demonstrated here,
can be advantageous over conventional methods of image
analysis.
Materials and Methods
Animals
A total of 52 pathogen-free adult male Sprague Dawley rats
(300–400 g; Harlan Labs, Madison, WI) were used in all ex-
periments. Rats were double housed in a temperature- and
light-controlled (12 h light/dark; lights on at 6:00 AM) en-
vironment, with standard rodent chow and water available
adlibitum.AllprocedureswereapprovedbytheInstitutional
Animal Care and Use Committee (IACUC) of the University
of New Mexico Health Sciences Center.
Drugs
The CB2R agonist used in these experiments was (R,S)-(2-
iodo-5-nitrophenyl)-(1-[(1-methylpiperidin-2-yl)methyl]-
1H-indol-3yl)-methanone(AM1241) from the aminoalkyn-
dole classiﬁcation (Yao et al. 2006). Water-soluble hy-
drochloride salt of racemic AM1241 was generously gifted
(A. Makriyannis, Center for Drug Discovery, Northeastern
University). Initial doses of AM1241 were based on those
previously reported for i.v. injection (Beltramo et al. 2006)
and pilot studies. A 1000-fold dose range of AM1241,
dissolved in sterile saline (Hospira Inc, Lake Forest, IL) was
tested (10–0.01 μgi n1 0μl) or equivolume sterile saline as
vehicle. Of note, fully solubilized AM1241 resulted in a clear
solution.
Behavioral assessment of allodynia
Baseline (BL) responses to light mechanical touch were as-
sessed using the von Frey test after animals were habituated
tothetestingenvironment,aspreviouslydescribed(Chaplan
etal.1994;Milliganetal.2000).Brieﬂy,ratswereplacedatop
2-mm bars with 8-mm spacing between parallel bars for ap-
proximately 45 min for ﬁve days. All behavioral testing was
performed during the ﬁrst half of the light cycle in a sound-,
light-, and temperature-controlled room. The von Frey test
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utilizes a series of calibrated monoﬁlaments (3.61–5.18 log
stimulus intensity; North Coast Medical, Morgan Hills, CA),
applied randomly to the left and right plantar surface of the
hindpaw for 8 sec. Lifting, licking, or shaking the paw was
considered a response. Following CCI or sham surgery, an-
imals were behaviorally tested on Day 3 and 10. On Day 10
post-surgeryafterbehavioralassessment,allanimalsreceived
an i.t. AM1241 or vehicle injection followed by behavioral
reassessment at 30 min intervals for 5 h and again at 24 h.
Testing was performed in a blinded fashion.
CCI surgery
Following BL behavioral assessment, the surgical procedure
forchronicconstrictionofthesciaticnervewascompletedas
previously described (Bennett and Xie 1988). Brieﬂy, isoﬂu-
rane (induction 5% volume followed by 2.5% in oxygen),
anesthetized rats had their mid-to-lower back and the dorsal
leftthighshavedandcleanedwithdilutedBacti-StatAE,(Eco-
LabHealthCareDivision,Mississauga,Ontario,Canada).Us-
ingasepticprocedures,thesciaticnervewascarefullyisolated
and loosely ligated with 4 segments of chromic gut sutures
(Ethicon, Somerville, NJ) with each suture approximately
1 mm apart. Sham surgery was identical to CCI surgery but
withoutthenerveligation.Theoverlyingmusclewassutured
closed with two 3–0 sterile silk sutures (Ethicon, Somerville,
NJ), and animals recovered from anesthesia within approxi-
mately 5 min.
Intrathecal (i.t.) injection
AM1241 was administered via acute i.t. catheter. Injections
were performed as previously described (Milligan et al.
2005b). Brieﬂy, rats were anesthetized with isoﬂurane and
an 18-gauge sterile, hypodermic needle, with the plastic hub
removed was inserted between lumbar vertebrae L5 and L6.
The PE-10 injection catheter was marked between 7.7 and
7.8 cm from an open end, with the other end inserted into a
30-gauge needle. A sterile Hamilton syringe was ﬁtted with
the30-gaugeneedleandtheattachedPE-10catheter,andcol-
lectivelyreferredtoasaninjectioncatheter.Either10μldrug
or equivolume vehicle was withdrawn from respective vials
via the open end of the PE-10 injection catheter, which was
gently inserted into the placed 18-gauge needle and threaded
rostrallytothe7.7cmmarkingontheinjectioncatheter.The
resulting position of the inserted tip of the PE-10 catheter
occurs at the i.t. lumbosacral enlargement (∼L4–L5). Dur-
ing this time, light tail twitching and a small amount of
cerebrospinal ﬂuid efﬂux from the 18-gauge needle was typ-
ically observed indicating successful i.t. catheter placement.
Drug or vehicle was injected during a 10-sec interval. Upon
completion of injection, the PE-10 i.t. catheter was removed
followed by removal of the 18-gauge needle. A 100% motor
recovery rate was observed from this injection procedure.
Immunohistochemical procedures
Following behavioral assessment at indicated time points
(Figs. 3, 4), animals were overdosed with an i.p. injection
(0.8-1.3cc)ofsodiumphenobarbital(Sleepaway,FortDodge
Animal Health, Fort Dodge, IA) and perfused transcardially
with saline followed by 4% paraformaldehyde. Whole ver-
tebral columns with intact spinal cord (cervical 2 through
sacral 1 spinal column segments) were removed, and under-
wentovernightﬁxationin4%paraformaldehydeat4◦C.This
tissue collection procedure ensured that all relevant anatom-
icalcomponents,includingthespinalcord,DRG,andrelated
meninges, were intact within the vertebral column, allowing
important spatial relationships to be examined for corre-
sponding functional interactions at individual and speciﬁc
spinal cord levels. All specimens underwent EDTA (Sigma
Aldrich,St.Louis,MO)decalciﬁcationfor30days,andspinal
cord sections were subsequently parafﬁn processed and em-
bedded in Paraplast Plus Embedding Media (McCormick
Scientiﬁc, St. Louis, MO) as previously described (Wallace
et al. 1996). Four adjacent tissue sections (7 μm) were
mounted on a vectabond-treated slide (Vector Labs,
Burlingame,CA),andallowedtoadheretotheslideovernight
at 40◦C.
Approximately 130 slides per L4–L6 lumbar spinal cord,
and 40 slides per lumbar L5 DRG, were generated in this
manner for each animal. Two slides from an animal’s lumbar
spinal cord and two slides of DRG were randomly chosen for
each staining procedure. The 7-μm sections then underwent
deparafﬁnization,andrehydrationviadescendingalcoholsto
phosphate buffered saline (PBS) (1×,p H7 . 4 ) .S e c t i o n sw e r e
then processed with microwave antigen retrieval procedures
(citrate buffer pH 6.0, or tris-based buffer, pH 9.0; BioCare
Medical, Concord, CA).
Antibody staining
Slideswereincubatedwith5%normaldonkeyserum(NDS),
in PBS (1×, pH 7.4) for 2 h, followed by overnight primary
antibody(Table1)incubationinahumiditychamberat3◦C.
Slides underwent secondary antibody incubation (Table 1)
f o r2hi nah u m i d i t yc h a m b e ra tr o o mt e m p e r a t u r e ,r i n s e d
inPBS,andthencoverslippedwithVectashieldcontainingthe
nuclearstain4 ,6-diamidino-2-phenylindole(DAPI)(Vector
Labs, Burlingame, CA). For detection of monoacylglycerol
lipase (MAGL), phosphorylated p38MAPK, and IL-10 pro-
tein, sections were incubated overnight with primary anti-
bodies, incubated with biotinylated secondary antibody (Ta-
ble 1) for 1 h, and then treated with Vectastain ABC Elite kit
(Vector Labs, Burlingame, CA) and stained using TSA Plus
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Table 1. List of all antibodies used in this study and designated under the appropriate column heading. Primary antibodies for polyclonal GFAP
(astrocyte-speciﬁc glial ﬁbriliary acidic protein, Millipore, Billerica, MA) previously used in other studies (Wu et al. 2002; Fukudome et al. 2003),
monoclonal GFAP (astrocyte-speciﬁc GFAP, Progen, Heidelberg, Germany) previously used in other studies (Achstatter et al. 1986), Iba-1 (microglia,
monocyte-speciﬁc calcium channel protein, Wako Chemicals, Osaka, Japan) previously used in other studies (Imai et al. 1996; Ohsawa et al. 2000),
FAAH (fatty acid amide hydrolase, endocannabinoid degradative enzyme, Cayman Chemicals, Ann Arbor, MI) previously used in other studies (Yasuo
et al.; Starowicz et al. 2008), IL-1β protein (proinﬂammatory cytokine, Santa Cruz Biotechnology, Santa Cruz, CA) previously used in other studies
(Bellucci et al. 2004; Reed et al. 2009), MAGL (monoacylglyerol lipase, endocannabinoid degradative enzyme, Abcam, Cambridge, MA) previously used
in other studies (Marquez et al. 2009), phosphorylated p38MAPK (activated proinﬂammatory cytokine signaling pathway, Cell Signaling Technology,
Beverly, MA) previously used in other studies (Schafers et al. 2003), and IL-10 protein (anti-inﬂammatory cytokine, R & D Systems, Minneapolis, MN)
previously used in other studies (Thompson–Snipes et al. 1991; Hor et al. 2004) were used. Secondary antibody incubation was performed with the
indicated ﬂuorophore-conjugated secondary antibody. For MAGL, phosphorylated p38MAPK, and IL-10 protein, after overnight primary incubation,
sections were instead incubated with biotinylated secondary antibody.
Primary Antibody Anatomical Vendor/ Dilution Antigen TSA Secondary
antibody clone Indication region Catolog number Host used retrieval used antibody
1
GFAP Polyclonal Astrocyte Dorsal horn
spinal cord
Millipore/AB5804 Rabbit 1:1000 Tris buffer No Rhodamine Red Donkey
anti-Rabbit (1:200)
GFAP MonoclonalSatellite cell DRG Progen/65011 Rabbit 1:10 Citrate buffer No Rhodamine Red Donkey
anti-Rabbit (1:200)
Iba-1 Polyclonal Microglia Dorsal horn
spinal cord
Wako/019–19741Rabbit 1:300 Tris buffer No Rhodamine Red Donkey
anti-Rabbit (1:200)
FAAH Polyclonal Ecb enzyme Dorsal horn
spinal cord
Cayman Chemi-
cal/101600
Rabbit 1:100 Tris buffer No Rhodamine Red Donkey
anti-Rabbit (1:200)
MAGL Polyclonal Ecb enzyme Dorsal horn
spinal cord
Abcam/
AB24701
Rabbit 1:100 Citrate buffer Yes Biotinylated Donkey anti-
Rabbit (1:1300)
p-p38 Polyclonal Phospho-p38
MAP Kinase
Dorsal horn
spinal
cord, DRG
Cell Signal-
ing/45112
Rabbit 1:800 Citrate buffer Yes Biotinylated Donkey anti-
Rabbit (1:1300)
IL-10 Polyclonal IL-10 protein Dorsal horn
spinal
cord, DRG
R & D Systems/
AF519
Goat 1:250 Citrate buffer Yes Biotinylated Donkey anti-
Goat (1:1300)
IL-1β Polyclonal IL-1β protein Dorsal horn
spinal
cord, DRG
Santa Cruz/SC-
7884
Rabbit 1:300 Tris buffer No FITC, Rhodamine Red
Donkey anti-Rabbit
(1:200)
1All secondary antibodies are from Jackson Immunoresearch (West Grove, PA).
Fluorescein System (PerkinElmer Life Sciences, Waltham,
MA) and ﬁnally coverslipped with Vectashield contain-
ing DAPI. Stained section orientation was kept consistent
throughout for proper identiﬁcation of ipsilateral and con-
tralateralspinal cordandDRGs. Forlumbarspinal cord, sec-
tions were taken from L4–L6 and the dorsal horn analyzed
(Fig. 1A). For DRG material, sections were taken containing
theDRGwiththeprojectiontoL5,andthemostdistalportion
of the DRG was analyzed (Fig. 1B). Low-magniﬁcation pho-
tomicrographswereobtained(Fig.1Aand1B)usingaNikon
OptiphotﬂuorescentmicroscopeequippedwithaDP2-BSW
(Olympus) camera.
Immunohistochemical image analysis
Image J software analysis
Fluorescent images for standard ﬂuorescence analysis were
obtained in the same manner as detailed above, with DAPI
omitted from the Vectasheild mounting media. This was to
ensurethatDAPIstainingdidnotpotentiallyobscuretheﬂu-
orescence intensity. Images were taken on an Olympus BX51
microscope (Center Valley, PA) equipped with an Olympus
DP72 camera. Images were then converted to gray scale and
analyzed using Image J software available for free download
at http://rsb.info.nih.gov/ij/. Brieﬂy, an outline of the dor-
sal horn gray matter was drawn on an image, and holding
the area within this outline consistent, the ﬂuorescent in-
tensity was obtained within this area for each image. This
value was generated for each given tissue section (e.g., ipsi-
lateral dorsal horn spinal cord) and averaged together (total
of four tissue sections from a single animal) for an overall
value. Therefore, for each anatomical location (e.g., ipsilat-
eral and contralateral dorsal horn spinal cord and DRG), the
four values (ﬂuorescent intensity average count/sec/mm2)
were averaged to obtain an individual animal’s overall ﬂu-
orescent intensity, with three animals in each experimental
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Figure 1. Anatomical location of images acquired and spectral analysis allows for discrete ﬂuorescence signal detection and analysis. (A) Hematoxylin
and eosin staining of the dorsal horn of the spinal cord and (B) dorsal root ganglion (area within black box) is displayed in context to relevant anatomical
structures (the entire spinal cord and partial cauda equina, respectively) at 4× magniﬁcation, and then at 20× magniﬁcation. (C) Representative
ﬂuorescent emission for DAPI (blue) FITC (light green), GFP (dark green) Rhodamine Red (red), and autoﬂuorescence (double black). Selection of
narrow ﬂuorescent peak emission bands (dotted black box around FITC wavelength) allows for analysis of only FITC signal, without autoﬂourescent
or GFP signal contaminating ﬂuorescent analysis. (D) Representative ﬂuorescent emission threshold level of FITC deﬁned and expanded from dotted
black box in (C) with the ﬂuorescent threshold of intensity set (dashed black line), above autoﬂuorescent levels. (E) Representative spectral image of
dorsal horn spinal cord as stained for GFAP (red), with autoﬂuorescent signal deﬁned in yellow. (F) Same image in (E) with autoﬂuorescent signal
removed. In all images the scale bar is equal to 50 μm.
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treatmentgroup,togenerateanaverageforthatexperimental
condition.Likewise,backgroundvaluesweregeneratedfrom
control tissues incubated with PBS and the given secondary
antibody, and averaged together. The average background
was then subtracted from the above-mentioned average of
each experimental treatment group.
Spectral analysis of images
All images of the spinal cord dorsal horn and DRGs were
capturedbyaZeissAxioscopeMicroscopeat20×magniﬁca-
tion with a Nuance Spectral Camera (Cambridge Research &
Instrumentation, Woburn, MA). Utilizing the Nuance com-
puter software, the ﬂuorescent wavelength emission spectra
was initially determined for each ﬂuorophore utilized in the
detectionoftheprimaryantibodyofinterest(DAPI,488±10
nm;FITC,575±5nm;RhodamineRed600±5nm)byusing
a control slide with only a drop of thepure ﬂuorophore.This
was performed in the absence of a tissue specimen that may
potentially obscure the measurement of the ﬂuorophore’s
emission spectra. Two sets of additional control slides with
tissue sections, one with only PBS without primary but with
secondary antibody treatment, and the other, with primary
but without secondary antibody treatment, were then used
to objectively eliminate low-intensity ﬂuorescence and aut-
oﬂuorescence background “noise” from our measurements
(Fig. 1C). Using control slides, the Nuance software allows
the user to set an acceptable threshold of low-level emis-
sion ﬂuorescent intensity (as opposed to the software’s “au-
tothreshold” option) within and outside the deﬁned wave-
length of interest between tissue samples. The experimenter
determinedlow-levelemissionintensitybycloselyreplicating
the composite computer image with that observed through
the eyepiece. Emission values that fall below this acceptable
threshold of low-level emission, within and outside the de-
ﬁned wavelength of interest, were eliminated from our mea-
surements (Fig. 1D). This level of ﬂuorescent threshold for
each protein marker was determined by the user, ﬁnding
the most appropriate wavelength of interest that captures
the speciﬁc FITC or Rhodamine Red staining for each pro-
tein marker within a tissue (e.g., dorsal horn spinal cord or
DRG). Once the optimal level of ﬂuorescent threshold was
determinedforaparticularproteinmarker,thislevelwasheld
consistentthroughoutallofthetreatmentgroupsfortheim-
age analysis (Fig. 1D). These steps were followed by software
conversion of ﬂuorescent wavelength intensity for each ﬂuo-
rophore to a numerical value. Autoﬂuorescence was deﬁned
as the emission outside the deﬁned wavelength of interest
(e.g., DAPI, 488 ± 10 nm; FITC, 575 ± 5n m ;R h o d a m i n e
Red 600 ± 5 nm). These speciﬁc autoﬂuorescent and low-
level background emission values were subtracted from the
image(Fig.1Eand1F),yieldinganumericalvalueoftrueﬂu-
orescent emission intensity for each ﬂuorophore (Mansﬁeld
et al. 2008; Mahad et al. 2009).
Primaryantibodystainingproceduresremainedconsistent
to minimize intensity variations of each ﬂuorophore (FITC
or Rhodamine Red) used to detect the different primary an-
tibodies of interest. To ensure that ﬂuorophore binding was
notimpededthroughpossiblesterichindranceofotherprox-
imalﬂuorophores,sectionswerelabeledforonlyonecellular
marker of interest on a slide.
The user also determined the minimum number of con-
nected pixels on the computer screen for image analysis,
counted as a region of interest (ROI) deﬁned in the Nuance
software system, which resulted in a software image con-
taining distinctive morphology (i.e., of cellular bodies and
processes, pattern of protein expression) that was virtually
identical to the morphology observed through the micro-
scope. The number of minimum connected pixels would
therefore be set higher for a protein expressed abundantly by
acell(i.e.,GFAP)thanaproteinexpressedsparsely,leadingto
a punctuate pattern (i.e., IL-1β). These conditions resulted
in a region of interest (ROI), and were held consistent for
both the ipsilateral and contralateral tissues in every experi-
mental condition and for each antibody stain. The total area
of each ROI, as measured by mm2, is calculated and is fac-
tored into the overall measurement of ﬂuorescent intensity
per second of exposure. The average count of ﬂuorescent
emission intensity per second exposure, per mm2 is the ana-
lyzed value that we report here. That is, ﬂuorescent intensity
averagecount/sec/mm2,whichtakesintoaccountthedensity
as well as the intensity of the ﬂuorophore detected. A total
of four sections per animal (N = 3) were randomly selected
and analyzed in this manner. By applying this novel method
of data acquisition and analysis, experimenter bias is greatly
minimized or even eliminated, yielding greater consistency
and objectivity to ﬂuorescent quantiﬁcation.
Data analysis
Psychometric behavioral analysis was performed as previ-
ously described (Milligan et al. 2000) to compute the log
stiffnessthatwouldhaveresultedinthe50%pawwithdrawal
rate. Brieﬂy, thresholds were estimated by ﬁtting a Gaussian
integral psychometric function to the observed withdrawal
ratesforeachofthetestedvonFreyhairs,usingamaximum-
likelihood ﬁtting method (Treutwein and Strasburger 1999).
Estimated thresholds derived from a Gaussian integral func-
tion yield a mathematical continuum and thus are appropri-
ate for parametric statistical analyses (Treutwein and Stras-
burger 1999; Milligan et al. 2000). The computer program
PsychoFit may be downloaded from L.O. Harvey’s website
(http://psych.colorado.edu/∼lharvey). All other data anal-
ysis was performed using the computer program GraphPad
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Figure 2. Intrathecal (i.t.) AM1241, a cannabinoid 2 receptor agonist reverses CCI-induced allodynia. (A and B) AM1241 reverses CCI-induced
allodynia in a dose-dependent manner. Before surgical manipulation, all AM1241 BL values of experimental groups exhibited similar ipsilateral and
contralateral BL thresholds; CCI surgery produced signiﬁcant bilateral allodynia at Day 3 and 10 following injury compared to sham-treated animals.
Responses from AM1241 (10 μg) maximally reversed CCI-induced allodynia, (black squares), at 1.5 h with allodynia fully returning by 3 h after i.t.
administration.
Prismversion4.03(GraphPadSoftwareInc.,SanDiego,CA).
ForbehavioralanalysistoassessBLvalues,aone-wayanalysis
ofvariance(ANOVA)wasapplied.Toexaminethepresenceof
allodynia,arepeatedmeasuresANOVAwasusedatBL,three
and 10 days after CCI, and indicated times note in above
section (Behavioral assessment of allodynia). For the initial
evaluation of ﬂuorescence fading (Fig. 3A and 3B), the Stu-
dent’s t test with a 95% conﬁdence interval was utilized. For
all other statistical analysis, a two-way ANOVA with a 95%
conﬁdence interval was performed. Statistical signiﬁcance
was determined with P-values < 0.05. All data are expressed
as mean± SEM. For post hoc analysis, Bonferroni’s test was
performed.
Results
Intrathecal (i.t.) injection of AM1241
reverses CCI-induced allodynia in a
dose-dependent manner
Limited evaluation exists for i.t. spinal application of CB2R
agonists to control allodynia produced by CCI, a widely used
and well-characterized rodent model of chronic peripheral
neuropathywithrelatedpain-likebehaviors(BennettandXie
1988). We ﬁrst examined if the putative CB2R agonist from
theaminoalkylindoleclass,AM1241(36-foldCB2R>CB1R)
(Yaoetal.2006;Thakuretal.2009),couldreverseongoingal-
lodynia produced by CCI. Prior to surgical manipulation, all
groups exhibited similar bilateral (ipsilateral and contralat-
eral) BL thresholds (ANOVA, F(5,35)= 1.105; P = 0.3764 and
ANOVA, F(5,35) = 2.632; P = 0.5884, respectively) (Fig. 2A
and2B).FollowingCCI,clearbilateralallodyniadevelopedby
Day 3 and continued chronically through Day 10 compared
to sham-operated rats (ANOVA, F(10,56) = 73.23; P < 0.0001
and ANOVA, F(10,56) = 71.32; P < 0.0001, respectively). On
Day 10, compared to i.t. control injected neuropathic rats,
AM1241 produced a dose-dependent reversal of allodynia,
withmaximalreversalobservedat1.5hfollowingthehighest
injected dose (10 μg ) .H o w e v e r ,a l l o d y n i af u l l yr e t u r n e db y
3 h after i.t. AM1241 treatment, with allodynia remaining
constant through 24 h. While 0.1 μg produced attenuated
allodynia, 0.01 μg did not alter allodynia for either the ip-
silateral (Fig. 2A) (ANOVA, F(15,84)= 138.8; P < 0.0001) or
contralateral(Fig.2B)hindpawresponses(ANOVA,F(15,84)=
131.6; P < 0.0001). Post hoc analysis revealed that 10 μg
AM1241 yielded maximal reversal similar to pretreatment
BL values at 1.5 h after injection (P > 0.05).
Spectral analysis versus standard Image
J ﬂuorescent analysis
Although previous reports detail an observed increase of IL-
1β IR within the dorsal horn of the spinal cord after nerve
ligation with chromic gut or silk sutures (Hashizume et al.
2000), detecting statistically signiﬁcant changes in IL-1β IR
hasbeenproblematic.Meanwhile,theuseofspectralanalysis
procedures in other studies has demonstrated increased ac-
curacy and sensitivity for the detection of cell-speciﬁc mark-
ers (Constantinou et al. 2009; Mahad et al. 2009; Andres
et al. 2010). We therefore made direct comparisons between
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standardﬂuorescentanalysiswithImageJsoftwareandspec-
tral image analysis software to identify the most sensitive
method to quantify immunoreactive proteins of interest.
Identical tissue sections for both analysis procedures were
used to eliminate potential ﬂuorescent intensity variance be-
tween slides. Additionally, FITC-conjugated secondary anti-
body was examined as well as Rhodamine-conjugated sec-
ondary antibody to identify whether intrinsic differences
between different ﬂuorophores (red vs. green) could yield
false-positive group differences.
IL-1β IR was examined with standard FITC ﬂuorescent
analysisutilizingNIHImageJsoftwareprocedures(Fig.3A).
While a trend toward differences was present using Image J
software, no statistically signiﬁcant increase in IL-1β IR in
either the ipsilateral or contralateral dorsal horn was found
between non-neuropathic (Sham-Vehicle) and neuropathic
CCI-treatedrats(Student’st test P =0.0620andP =0.5142,
respectively). We utilized FITC-tagged secondary antibody
in these studies because FITC tends to fade at a greater rate
than Rhodamine Red, providing a stringent assessment of
potential observed differences between experimental groups
following a subsequent exposure. We therefore exposed the
same tissue sections analyzed in Figure 3A for a second time
(Fig. 3B) with double the exposure duration, but with the
light sensitivity held consistent. Doubling the exposure time
provides a rigorous test to determine whether fading can in-
ﬂuence quantitative results. In using Image J, marginal non-
signiﬁcant fading of ﬂuorescent intensity (Fig. 3A vs. 3B)
(Student’s t test P = 0.7418 and P = 0.9060, respectively)
was present, and no difference in IL-1β IR between non-
neuropathic and neuropathic rats was detected (Student’s t
testP=0.0648andP=0.4874,respectively).Inthesamecon-
text, marginal fading was observed with spectral microscopy
exposure between an initial exposure and a subsequent ex-
posure (data not shown).
Given that ﬂuorophore fading was not present upon sub-
sequent exposures, a new set of FITC-stained IL-1β tissues
from nonneuropathic (Sham-Vehicle) and neuropathic rats
(CCI-Vehicle) treatment groups were examined with stan-
dard Image J ﬂuorescence analysis followed by spectral anal-
ysis.WithImageJ,wefoundnosigniﬁcanteffectofsurgeryin
eitheripsilateralorcontralateraldorsalhorn(Studentt testP
= 0.5604 and P = 0.6988, respectively) (Fig. 3C). However,
spectral analysisoftheidenticalsectionsrevealedstatistically
signiﬁcant differences in ipsilateral IL-1β IR due to surgi-
cal treatment (Student’s t test P = 0.0482 and P = 0.0635,
respectively) (Fig. 3D).
We found similar effects following comparison with a new
set of slides from L4–L6 lumbar spinal cord tissue sections
treated with IL-1β primary antibody, but incubated with a
secondary antibody conjugated to the Rhodamine Red ﬂu-
orophore (Fig. 3E and 3F). That is, the quantitative results
between FITC or Rhodamine Red ﬂuorescent intensity were
similarwithineachmethodofimageanalysis.Speciﬁcally,no
signiﬁcant effect from surgical treatment was found utilizing
standard Image J Rhodamine Red ﬂuorescence analysis be-
tweentreatmentgroups,eitheripsilaterallyorcontralaterally
(Student’s t test P = 0.2918 and P = 0.2023, respectively)
(Fig. 3E), while incorporating spectral analysis methods of
the same tissues revealed strong increases in ipsilateral but
not contralateral IL-1β IR in CCI-treated rats (chronic neu-
ropathy)(Student’st testP =0.0096andP =0.1047,respec-
tively) (Fig. 3F). Representative tissue staining for sham and
CCI IL-1β are shown, as acquired with standard ﬂuorescent
microscopy (Fig. 3G and 3H) and with spectral ﬂuorescent
microscopy (Fig. 3I and 3J). Thus, these ﬁndings demon-
strate that the use of spectral analysis may yield quantitative
differences that may have previously gone undetected utiliz-
ing standard immunohistochemistry analysis techniques.
Behavioral veriﬁcation of i.t. AM1241
for subsequent spinal cord
immunohistochemistry
In a separate group of rats, i.t. injection of AM1241 again
produced robust bilateral reversal from allodynia (Fig. 4A
and 4B), similar to that observed in Figure 2. Prior to
CCI, all groups exhibited similar ipsilateral and contralat-
eral BL thresholds (ANOVA, F(3,11) = 0.9006; P = 0.4821
andANOVA,F(3,11) =0.8916;P =0.4860,respectively).CCI
produced signiﬁcant bilateral allodynia at Day 3 and contin-
ued to Day 10 compared to sham-treated animals (ANOVA,
F(1,8) = 135.8; P < 0.0001 and ANOVA, F(1,8) = 149.9;
P = 0.0001, respectively). Behavioral responses following i.t.
AM1241 (10 μg) produced maximal bilateral reversal of al-
lodynia (ANOVA, F(1,8) = 150.4; P < 0.0001 and ANOVA,
F(1,8) =72.36;P <0.0001,respectively).Atpeakreversal,an-
imalsweresacriﬁcedandspinaltissuewascollectedtoexam-
inebilateralIRforproteinsincludingcytokinesp-p38MAPK,
glial activation markers, and endocannabinoid degradative
enzymes.
Immunohistochemical analysis of spinal cord
dorsal horn
IL-10
WhilespinalCB2Ractivationcontrolspain-relatedbehaviors
and glial activation in neuropathic rats (Zhang et al. 2003;
Romero–Sandoval and Eisenach 2007; Racz et al. 2008a,b;
Romero–Sandoval et al. 2008b), the underlying spinal im-
munoregulatory signals remain unclear. One of the most
effective anti-inﬂammatory cytokines characterized to con-
trol pathological pain processing to date is IL-10 (Plunkett
etal.2001;Milliganetal.2005a,b,2006;Ledeboeretal.2006;
Sloane et al. 2009a,b; Soderquist et al. 2010a,b). Here, we
examined changes in IL-10 IR at the time of peak AM1241
efﬁcacy. Bilateral IL-10 IR in the dorsal horn spinal cord
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Figure 3. Spectral versus standard Image J
immunoﬂuorescent intensity quantiﬁcation
comparison. (A) Utilizing Image J software for
immunoﬂuorescent quantiﬁcation, no
signiﬁcant IL-1β IR differences between
CCI-induced neuropathy or nonneuropathic
sham-treated rats in either the ipsilateral or
contralateral dorsal horn of the spinal cord.
IL-1β IR was observed by FITC-labeled
secondary antibody. (B) Following a second
exposure for image capture, ﬂuorophore
fading was virtually absent thereby lacking
potential artiﬁcial IR intensity differences
between experimental conditions. (C)A
comparison of sham- and CCI-treated rats
with i.t. vehicle using Image J
immunoﬂuorescent quantiﬁcation resulted in
no signiﬁcant ﬂuorescent intensity differences
of labeled IL-1β IR between groups, in either
the ipsilateral or contralateral dorsal horn. (D)
Utilizing spectral immunoﬂuorescent
quantiﬁcation, signiﬁcant differences of
ﬂuorescent intensity from FITC-labeled IL-1β
between sham- and CCI-treated rats given i.t.
vehicle was observed in the ipsilateral, but not
contralateral dorsal horn spinal cord. (E)A n
examination of ﬂuorescent intensity between
groups with a ﬂourophore of a different
spectral signature, Rhodamine Red (600 nm),
using standard Image J immunoﬂuorescent
quantiﬁcation revealed no signiﬁcant group
differences between sham- and CCI-treated
rats despite a trend of increased IL-1β IR in
CCI-treated rats with i.t. vehicle in either the
ipsilateral or contralateral dorsal horn. (F)
Spectral immunoﬂuorescent quantiﬁcation of
Rhodamine Red labeled IL-1β yielded
signiﬁcant group differences between
nonneuropathic sham rats and CCI-treated
rats with vehicle in the ipsilateral dorsal spinal
cord. IL-1β IR increases were absent in the
contralateral dorsal horn. (G, H)
Representative ﬂuorescent images analyzed
with Image J at 20× magniﬁcation of IL-1β
ﬂuorescent labeling (red). (I, J) Representative
spectrally unmixed images at 20×
magniﬁcation of IL-1β ﬂuorescent labeling
(red) with DAPI nuclear stain (blue). In all
images, the scale bar is equal to 50 μm. All
sections were 7-μm thick, and collected 1.5 h
after i.t. vehicle administration 10 days after
CCI or sham surgery.
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Figure 3. Continued
was dramatically decreased in CCI-induced neuropathic rats
compared to sham-treated rats (ANOVA, F(1,8)= 10.09; P=
0.0131 and ANOVA, F(1,8)= 7.548; P= 0.0252, respectively),
(Fig. 4C and 4D). In stark contrast, treatment with AM1241
resultedinbasallevelsofIL-10IR,forboththeipsilateraland
contralateral dorsal spinal cord (ANOVA, F(1,8)= 13.19; P=
0.0067andANOVA,F(1,8)=7.903;P=0.0228,respectively).
IL-1β
To replicate our results described in Figure 3D and 3F, sepa-
rate L4–L6 lumbar spinal cord tissue sections were processed
andanalyzed.Comparedtonon-neuropathicsham-operated
rats given i.t. AM1241 or equivolume vehicle, CCI-induced
neuropathy produced a robust unilateral increase in dor-
sal horn IL-1β IR (ANOVA, F(1,8) = 10.46; P = 0.0120),
while, compared to controls, no differences in contralateral
IL-1β were observed (ANOVA, F(1,8) = 1.627; P = 0.2379)
(Fig. 4E and 4F). Conversely, following AM1241 adminis-
tration, signiﬁcantly lower levels of IL-1β IR were detected
(ANOVA, F(1,8) = 9.431; P = 0.0153). IL-1β IR observed
in the contralateral dorsal horn was not substantially ele-
vated when compared to vehicle-injected animals (ANOVA,
F(1,8) = 1.321; P = 0.2836).
p38-MAPK and DAPI
Spinalp-p38MAPKiswidelycharacterizedtomediateallody-
niathroughtheactionsofspinalIL-1β (JiandSuter2007;Jiet
al. 2009). Therefore, p-p38MAPK was examined. Compared
to non-neuropathic sham-operated rats given i.t. AM1241
or equivolume vehicle, CCI-induced neuropathy produced a
robust p-p38MAPK bilateral IR increase in the spinal cord
dorsalhorn(ANOVA,F(1,8)=223.1;P <0.0001andANOVA,
F(1,8) = 148.0;P < 0.0001,respectively) (Fig.4Gand4H).In
contrast, tissues from rats treated with i.t. AM1241 revealed
dramatically lower levels of p-p38MAPK IR that were close
to or similar to spinal cord tissues from non-neuropathic
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Figure 4. Immunoﬂuorescent intensity quantiﬁcation from 7-μm thick sections of dorsal horn spinal cord from behaviorally veriﬁed rats following
i.t. vehicle or AM1241. (A, B) Prior to CCI, all groups exhibited similar ipsilateral and contralateral BL thresholds. CCI produced signiﬁcant bilateral
allodynia at Day 3 and 10 following injury compared to sham-treated animals. Behavioral responses following AM1241 (10 μg) produced maximal
bilateral reversal of allodynia followed by tissue collection of immunoﬂuorescent intensity quantiﬁcation. (C, D) IL-10 expression was bilaterally
decreased in CCI-treated rats that received i.t. vehicle compared to control sham-treated rats given either vehicle or AM1241, while IL-10 IR recovered
to sham levels in CCI neuropathic rats given i.t. AM1241. (E, F) Compared to sham controls, IL-1β expression was increased ipsilaterally, but not
contralaterally in CCI-treated animals given i.t. vehicle of AM1241. However, i.t. AM1241 in CCI-treated rats robustly suppressed increases in IL-1β
IR. (G, H) Phospho-p38 expression was bilaterally increased in CCI-induced neuropathic rats treated with i.t vehicle of AM1241. Increased bilateral
p-p38MAPK was signiﬁcantly suppressed in CCI-treated rats given i.t. AM1241. (I, J) No differences in DAPI nuclear stain ﬂuorescent intensity were
observed in either sham control or CCI-treated rats given either i.t. vehicle or AM1241. (K, L,a n dM) Representative spectrally unmixed images at
20× magniﬁcation of p-p38 MAPK ﬂuorescent labeling (green) with DAPI nuclear stain (blue). In all images, the scale bar is equal to 50 μm.
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sham-treated rats (ANOVA, F(1,8) = 85.82; P < 0.0001 and
ANOVA, F(1,8) = 187.1; P < 0.0001, respectively). Repre-
sentative ﬂuorescent images are presented corresponding to
the image analysis of either sham treated with i.t. vehicle
(Fig.4K),CCItreatedwithi.t.vehicle(Fig.4L),orCCItreated
with AM1241 (Fig. 4M).
It is possible that overall changes in spinal cord cell num-
bers could dramatically alter dorsal horn immunoﬂuores-
cent intensity quantiﬁcation, as proliferation of microglia
(Suter et al. 2009), astrocytes (Tsuda et al. 2011), or leuko-
cyte CNS extravasation (Xu et al. 2007) have been reported.
Consequently, cells could simply be constitutively express-
ing low levels of proteins, thus diminishing interpretation
that a protein-speciﬁc cellular response has occurred follow-
ing either CCI and/or i.t. AM1241. However, we observed
no change in cell numbers as assessed by quantiﬁcation of
nuclear-speciﬁcDAPIﬂuorescenceintensityasaconsequence
of either CCI procedures (ANOVA, F(1,8) = 0.1076; P =
0.7514 and ANOVA, F(1,8) = 0.7780; P = 0.4035, respec-
tively) or i.t. drug injections (ANOVA, F(1,8) = 0.04328; P =
0.8404 and ANOVA, F(1,8) = 0.06960; P = 0.7986, respec-
tively) (Fig. 4I and 4J).
Microglial and astrocyte activation
Iba-1 to identify altered microglial responses
B a s e do nr e p o r t e de v i d e n c et h a tC B 2Rs are present on mi-
croglia, we examined whether bilateral dorsal spinal mi-
croglialresponsesduringCCI-inducedallodyniawerealtered
subsequent to i.t. administration of AM1241. To examine
microglia in the dorsal horn of the spinal cord, expression
of the microglial marker, Iba-1 was examined. Compared
to non-neuropathic sham-operated rats given i.t. AM1241
or equivolume vehicle, CCI-induced neuropathy produced
a robust bilateral increase in spinal cord dorsal horn Iba-
1 IR (ANOVA, F(1,8) = 212.0; P < 0.0001 and ANOVA,
F(1,8) = 62.28; P < 0.0001, respectively) (Fig. 5A and 5B).
Surprisingly, AM1241 did not alter increased levels of spinal
dorsal horn Iba-1 IR in behaviorally reversed rats (ipsilateral
ANOVA, F(1,8) = 2.767; P = 0.1348, contralateral ANOVA,
F(1,8) =0.1346;P =0.7232)(Fig.5Aand5B).Representative
images taken from the spinal cord dorsal horn following i.t.
vehicle injection in sham- and CCI-treated rats are provided
(Fig. 5C and 5D).
GFAP to identify altered astrocyte responses
In the superﬁcial dorsal horn, where incoming signals from
painﬁbersareprocessed,histologicalobservationrevealsthat
astrocytes make intimate contact with microglia that express
CB2Rs (Romero–Sandoval et al. 2008a). Prior reports addi-
tionally show that following spinal CB2Ra c t i v a t i o ni nn e u -
ropathicrats,superﬁcialdorsalhornGFAPIRissigniﬁcantly
reduced(Romero–Sandovaletal.2009).Therefore,weexam-
inedGFAPIRinthedorsalhornfollowingi.t.administration
of AM1241. Compared to non-neuropathic control animals,
neuropathic rats demonstrated a robust bilateral increase in
dorsal horn GFAP IR (ipsilateral ANOVA, F(1,8) = 15.00;
P =0.0047;contralateralANOVA,F(1,8) =10.45;P =0.0120)
(Fig. 5E and 5F). In stark contrast, lower values of bilateral
GFAP IR were observed from tissues of rats treated with i.t.
AM1241(ipsilateralANOVA,F(1,8) =41.38;P =0.0002;con-
tralateral ANOVA, F(1,8) = 17.63; P = 0.0030) (Fig. 5E and
5F). Corresponding representative ﬂuorescent images used
for analysis are shown; sham-operated rats treated with ei-
ther i.t. AM1241 or equivolume vehicle (Fig. 3G and 3H), or
CCI-treated rats injected with either i.t. AM1241 or equivol-
ume vehicle (Fig. 3I and 3J).
Monoacylglycerol lipase (MAGL) and fatty
acid amide hydrolase (FAAH)
MAGL
Endocannabinoids known to produce anti-allodynic effects
are metabolized via enzymatic hydrolysis by fatty acid amide
hydrolase (FAAH) and/or MAGL (Basavarajappa 2007). In-
hibition of FAAH or MAGL increases the bioavailablity of
CNS endocannabinoids with a corresponding attenuation of
neuropathic pain rats (Kinsey et al. 2009; Long et al. 2009).
WhetherFAAHandMAGLIRexpressionlevelsarealteredin
thedorsalhornfollowingi.t.CB2Ragonistinjectionsinneu-
ropathic rats, is unknown. Therefore, we examined potential
changes in MAGL and FAAH IR in tissue sections from rats
given i.t. AM1241. Compared to non-neuropathic control
rats, neuropathic rats showed a robust ipsilateral (ANOVA,
F(1,8) = 34.19; P = 0.0004) and contralateral (ANOVA, F(1,8)
= 27.51; P = 0.0008) increase in dorsal horn MAGL IR (Fig.
6A and 6B). In contrast, spinal tissue collected from rats
given an i.t. AM1241 injection revealed signiﬁcantly lower
bilateral MAGL IR (ipsilateral ANOVA, F(1,8) = 8.356; P =
0.0202; contralateral ANOVA, F(1,8) = 4.146; P = 0.0761,
respectively) (Fig. 6A and 6B). Interestingly, no interpretable
ormeaningfulchangeinFAAHIRbetweennon-neuropathic
and neuropathic CCI rats was observed following surgical
manipulation(ipsilateralANOVA,F(1,8) =8.072;P =0.0218;
contralateral ANOVA, F(1,8) = 0.09666; P = 0.7638), or fol-
lowing i.t. AM1241 or vehicle treatment (ANOVA, F(1,8) =
0.5436; P = 0.4820 and ANOVA, F(1,8) = 2.174; P = 0.1786,
respectively) (Fig. 6C and 6D).
DRG Immunohistochemical analysis: GFAP,
IL-1β, p-p38MAPK, and IL-10
Immunohistochemical detection of GFAP, IL-1β,p -
p38MAPK, and anti-inﬂammatory IL-10 in L4–L5 DRG that
correspond to the ipsilateral and contralateral spinal cord
segments was quantiﬁed. Results revealed that compared to
non-neuropathiccontrolrats,CCI-inducedneuropathicrats
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Figure 5. Immunoﬂuorescent intensity
quantiﬁcation of the spinal cord dorsal horn
reveals differences in astrocyte activation but not
microglial activation in neuropathic rats treated
with AM1241. (A, B) Iba-1 expression increased
within the ipsilateral and contralateral dorsal
horn of the spinal cord following CCI
manipulations compared to control sham
treatment, irrespective of i.t. vehicle or AM1241.
(C, D) Representative spectrally unmixed images
at 20× of Iba-1 ﬂuorescent staining (red) and
DAPI nuclear stain (blue). (E, F)G F A P
immunoﬂuorescent intensity in the dorsal horn
of the spinal cord was signiﬁcantly increased in
neuropathic rats following CCI given i.t. vehicle,
while GFAP IR in neuropathic rats given i.t.
AM1241 was greatly attenuated. (G, H, I,a n dJ)
Representative spectrally unmixed images at
20× magniﬁcation of GFAP ﬂuorescent labeling
(red) with DAPI nuclear stain (blue). In all images,
the scale bar is equal to 50 μm. All sections
were 7 μm in thickness.
displayed a robust bilateral increase in GFAP IR in DRG (ip-
silateral ANOVA, F(1,8) = 9.133; P = 0.0165; contralateral
ANOVA, F(1,8) = 8.443; P = 0.0197, respectively) (Fig. 7A
and7B).However,i.t.AM1241injectionrobustlyblockedbi-
lateral increases in GFAP IR (ipsilateral ANOVA, F(1,8) =
27.19; P = 0.0008; contralateral ANOVA, F(1,8) = 5.223;
P = 0.0516, respectively) (Fig. 7A and 7B). Intriguingly,
D R Gc h a n g e si nl e v e l so fp - p 3 8 M A P KI Ro c c u r r e di nt h e
ipsilateral (ANOVA, F(1,8) = 6.885; P = 0.0305), but not the
contralateral DRG (ANOVA, F(1,8) = 0.2013; P = 0.6656) to
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Figure 6. Immunoﬂuorescent intensity quantiﬁcation of the spinal cord dorsal horn reveals that AM1241 reduces the expression of the endocannabi-
noid degradative enzyme, MAGL but does not alter FAAH. (A, B) Compared to control rats, MAGL IR expression was increased ipsilaterally, with strong
trends contralaterally in CCI-treated neuropathic rats that received i.t vehicle of AM1241, while spinal MAGL IR in CCI-treated rats given i.t. AM1241
was substantially reduced. (C, D) No changes in FAAH IR expression in ipsilateral and contralateral dorsal horn of either sham- or CCI-neuropathic rats
given either i.t. vehicle or AM1241 was observed. All sections were 7 μm in thickness.
the sciatic nerve damage (Fig. 7C and 7D), and i.t. AM1241
injection revealed ipsilateral p-p38MAPK IR that was sim-
ilar to controls (ANOVA, F(1,8) = 15.92; P = 0.0040). No
change in p38MAPK IR was detected in the contralateral
DRG (ANOVA, F(1,8) = 2.051; P = 0.1900). This unilateral
change was also observed with IL-1β IR due to CCI surgery
(ipsilateral ANOVA, F(1,8) = 6.414; P = 0.0351; contralat-
eral ANOVA, F(1,8) = 0.3111; P = 0.5923), and AM1241
treatment resulted in levels similar to controls (ipsilateral
ANOVA, F(1,8) = 52.03; P < 0.0001; contralateral ANOVA,
F(1,8)= 0.2221; P = 0.6500) (Fig. 7E and 7F). An intriguing
unilateral decrease in IL-10 IR was measured in CCI neu-
ropathic rats only (ipsilateral ANOVA, F(1,8) = 17.42; P =
0.0031; contralateral ANOVA, F(1,8) = 1.583; P = 0.2438),
while an i.t. AM1241 injection resulted in increased IL-10
IR levels that were similar to controls (ipsilateral ANOVA,
F(1,8) = 22.83; P = 0.0014; contralateral ANOVA, F(1,8) =
1.327; P = 0.2826) (Fig. 7G and 7H). Collectively, these data
show that while GFAP-positive satellite cells in bilateralDRG
are a target of AM1241, only ipsilateral IL-1β, p-p38MAPK,
and IL-10 IR levels are altered.
Discussion
In the present study, we examined the efﬁcacy of an i.t. CB2R
agonist, AM1241, on chronic bilateral allodynia produced
by unilateral sciatic nerve CCI. We present evidence that
AM1241producedrobustbilateralreversalfromallodyniain
adose-dependentmannerthatmayactviaanti-inﬂammatory
mechanisms. While prior reports show that peripheral ad-
ministration of AM1241 controls peripheral neuropathy in-
duced by spinal nerve ligation (Ibrahim et al. 2003; Yao
etal.2009),painfromcancerchemotherapeuticagents(Rahn
etal.2007,2010),andotherpathologicalpainstates(Nackley
et al. 2004; Beltramo et al. 2006; Rahn et al. 2008; Yao et al.
2009), the current results extend these ﬁndings by showing
that peri-spinal i.t. AM1241 injection acts to reverse CCI-
induced allodynia. Importantly, AM1241 itself did not al-
ter normal basal sensory threshold responses at any dose
when administered intrathecally, which is distinct from re-
ports showing an anti-nociceptive action at peripheral nerve
terminals following peripheral administration of AM1241
that produced increased BL sensory thresholds (Ibrahim et
al. 2006; Khanolkar et al. 2007; Rahn et al. 2010).
In this study, we additionally present evidence for distinct
proﬁles of anti-inﬂammatory protein expression patterns in
thedorsalhornofthespinalcordandDRG.Inthedorsalhorn
of neuropathic rats, bilateral IL-10 IR was signiﬁcantly lower
compared to non-neuropathic rats. While a reduction of pe-
ripheral nerve or DRG IL-10 mRNA or protein has been re-
ported(Schafersetal.2003;Jancaleketal.2010,2011),todate,
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Figure 7. Immunoﬂuorescent intensity quantiﬁcation of 7 μm in thick sections from the dorsal root ganglion reveals signiﬁcant differences in satellite
cell activation, phosphorylated p38MAPK, IL-1β, and IL-10 in i.t. AM1241-injected rats. (A, B) GFAP (satellite cell activation) expression was increased
in animals with CCI compared to sham-treated rats, given i.t. vehicle ipsilaterally as well as contralaterally, and robust bilateral suppression of GFAP
IR was observed in rats given i.t. AM1241. (C, D) A small but signiﬁcant unilateral increase in Phospho-p38 (activated) IR was detected on the side
ipsilateral to the CCI treatment with i.t. vehicle, while i.t. AM1241 attenuated increased p-p38MAPK IR in CCI-treated rats. (E, F) Unilateral IL-1β IR
was increased in DRG on the side ipsilateral to the CCI manipulation compared to sham-treated controls, while IL-1β expression was substantially
decreased in CCI-treated rats with i.t. AM1241. (G, H) Ipsilateral, but not contralateral, IL-10 IR was signiﬁcantly decreased in CCI-treated neuropathic
rats given i.t. vehicle of AM1241 compared to sham controls given either i.t. vehicle or AM1241. However, a robust increase in IL-10 IR in the DRG of
CCI-neuropathic rats given i.t. AM1241 was detected.
no prior reports have demonstrated decreased dorsal horn
IL-10 IR in adult rats during chronic allodynia from periph-
eral neuropathy. Additionally, greater bilateral p-p38MAPK,
astrocyte GFAP, microglial Iba-1, and MAGL IR levels were
measured in neuropathic rats compared to non-neuropathic
controls. Further, an increase in unilateral spinal IL-1β IR
was measured on the side ipsilateral to CCI. However, fol-
lowing an i.t. AM1241 injection, not only was behavioral
allodynia reversed, but IL-10, p-p38MAPK, astrocyte GFAP,
MAGL, and IL-1β IR levels were similar to those observed
innon-neuropathicanimals.ThecorrespondingL4–L5DRG
immunoﬂuorescent analysis from neuropathic rats revealed
similar changes in protein expression patterns, however, bi-
lateralDRGchangeswereobservedonlywithGFAPIR.These
data extend prior reports that AM1241 acts in a general anti-
inﬂammatory manner by identifying speciﬁc in vivo spinal
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and DRG changes of elevated IL-10, with concurrently di-
minished IL-1β and p-p38MAPK IR in the dorsal horn of
the spinal cord.
The pattern of bilateral allodynia reported in the current
study supports a number of prior reports demonstrating a
similar behavioral pattern from CCI (Paulson et al. 2000,
2002; Spataro et al. 2004; Milligan et al. 2005a,b; Xu et al.
2007; Bessiere et al. 2009; Dubovy et al. 2010). Bilateral
biochemical changes in the spinal cord and the DRG have
been examined that may, in part, characterize underlying
contralateral allodynia from CCI. These studies reported de-
creased α2-adrenergic receptor mRNA expression (Leiphart
et al. 2003), increased neuronal Fos protein (Ro et al. 2004),
increasedTNF-α protein(Schafersetal.2003),andincreased
IL-6 mRNA expression (Dubovy et al. 2010). Very recent re-
ports have demonstrated increases in unilateral spinal IL-1β
mRNAexpression(Shietal.2011),orincreasedIL-1β spinal
immunohistochemical detection (Sinicaclo et al. 2011), fol-
lowing unilateral sciatic nerve ligation or transection. Here,
we demonstrate the unique ﬁndings that an ipsilateral in-
crease in IL-1β IR is observed in anatomically intact spinal
cord following CCI that produces bilateral allodynia. It is
notable that the actions of spinal IL-1β are necessary for
allodynia produced from CCI (Milligan et al. 2006, 2005a).
Together,thesedatasuggestthatipsilateralIL-1β isimportant
for initiating changes that ultimately spread to the contralat-
eral spinal cord resulting in contralateral allodynia. Given
astrocytes can communicate via gap junctions, it is possible
that ipsilateral IL-1β-to-astrocyte communication leads to
the spread of contralateral astrocyte activation via gap junc-
tions inducing signals that result in contralateral allodynia.
In support of this hypothesis, a model of localized unilateral
sciatic nerve inﬂammation was demonstrated to critically
involve spinal astrocyte gap-junctional communication un-
derlying bilateral allodynia, which was mediated, in part, by
spinalIL-1β (Spataroetal.2004).Giventheindirectrolethat
ipsilateral IL-1β may play in contralateral allodynia, the key
biochemical difference between ipsilateral and contralateral
spinal cord may be in IL-1β expression patterns.
Inthecurrentdatareportedhere,wehaveidentiﬁedsignif-
icant increases of IL-1β IR in anatomically discrete regions
of the spinal cord in CCI-induced neuropathic rats as a con-
sequence of identifying and omitting autoﬂuorescence and
low-level background emission intensities from tissue sam-
ples.Thiswasachievedbyapplyingrelativelystraightforward
s p e c t r a la n a l y s i s ,u s i n gt h eN u a n c es o f t w a r e ,t oq u a n t i f yi m -
munoﬂuorescentlevelsinanatomicallyintactspinalcordthat
eliminates unwanted autoﬂuorescence occurring at nearby
wavelengths, which is not discernable using conventional
m e t h o d so fi m m u n o ﬂ u o r e s c e n c ed e t e c t i o na n dq u a n t i ﬁ c a -
tion.Furthermore,wereportthati.t.AM1241resultedinlow-
level IR for IL-1β similar to non-neuropathic control levels
that corresponds to anti-allodynia, suggesting that AM1241
inhibits IL-1β actions. Indeed, a prior report demonstrated
that endogenous IL-1β receptor antagonist, IL-1RA, con-
tributes to the anti-inﬂammatory effects of activated CB2
receptors(Molina–Holgadoetal.2003).Importantly,thedis-
creteIL-1β differencebetweenexperimentalgroupsdetected
in the current study was lost when applying standard Image
J analysis methods.
The most striking feature of applying spectral analysis
to tissue sections with ﬂuorescently tagged protein mark-
ers is that autoﬂuorescent emission peaks at nearby wave-
lengths can be determined from control tissue specimens
not stained for the protein marker under examination. The
identiﬁed autoﬂuorescent wavelengths with corresponding
intensity can be subtracted from images derived from tis-
suesthathaveundergonespeciﬁcimmunohistochemicalﬂu-
orescence staining procedures. This feature of subtracting
“noise” is advantageous when considering that sections be-
tween animals within a single experimental group can dis-
play variations in peak autoﬂuorescence intensity. Of critical
importance is that low-level ﬂuorescence emission within a
discrete 10-nm ﬂuorescent wavelength range being analyzed
(e.g., FITC 575 nm, ± 5 nm) can occur in the absence of
targeted immunoﬂuorescence protein staining thereby con-
tributing to background “noise.” This noise is detected by
applying the consistent use of both a ﬁxed contiguous pixel
numberandﬂuorescentthresholdduringimagecapture.The
identiﬁed endogenous ﬂuorescent intensity is then omitted
from quantiﬁcation of speciﬁc markers in the image. These
additional steps ensure experimenter bias is eliminated. A
practical consideration is that the spectral analysis software
iseasilylearnedandﬂuorescence-intensityquantiﬁcationcan
be conducted in a timely manner. An additional advantage
applying immunoﬂuorescent quantiﬁcation following spec-
tralanalysisofintactspinalcordisgreatersensitivitytodetect
speciﬁc protein markers compared to other protein quantiﬁ-
cation procedures that require relatively high amounts of
tissue samples (e.g., 100 μg). These traditional methods of-
tentranslate into the necessity forgreateranimalnumbersto
achieve detectable results.
Proinﬂammatoryfactorswereexaminedinthisreportthat
extend beyond IL-1β in an attempt to provide a broad char-
acterization of the anti-inﬂammatory effects of CB2Ra g o -
nists such as AM1241. The MAPK family consists of three
major members that includes p38, which as noted above,
contributes to pain sensitization following peripheral nerve
injury (Jin et al. 2003; Svensson et al. 2003, 2005a,b; Zhuang
et al. 2005, 2007; Ji et al. 2009; Sorkin et al. 2009; Suter et al.
2009) via the actions of spinal IL-1β and other proinﬂam-
matory cytokines (Liu et al. 2007; Kawasaki et al. 2008). The
current data support these prior reports in that increased
p-p38MAPK IR is present in the dorsal horn of the spinal
cord and DRG in neuropathic rats, and extend AM1241
characterization as an anti-inﬂammatory CB2Ra g o n i s tb y
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demonstrating that AM1241 robustly suppresses p-
p38MAPK IR in pain-reversed rats with peripheral
neuropathy.
Here, utilizing microglial and astrocyticmarkers in the
spinalcorddorsalhorninneuropathicrats,asassessedbyim-
munoﬂuorescentdetection, reveals increasedglialresponses,
in support of prior reports (Schreiber et al. 2008; Obata
et al. 2010). Dorsal horn spinal cord astrocyte and microglial
responses are recognized to mediate pathological pain in a
variety of animal models via p-p38MAPK and IL-1β ac-
tions (DeLeo et al. 2007; Ji and Suter 2007; Scholz and Woolf
2007). In the CNS, CB2R mRNA and immunohistochemi-
cally identiﬁed protein expression is present mostly in spinal
microglia(Zhangetal.2003;Romero–SandovalandEisenach
2007; Cabral et al. 2008; Romero–Sandoval et al. 2008a; Racz
etal.2008b),andpriorstudiesreporteddecreasedmicroglial
activation following i.t. administration of CB2Ra g o n i s t s
(Romero–Sandoval and Eisenach 2007; Romero–Sandoval
et al. 2009; Toth et al. 2010). Studies examining spinal cords
of transgenic CB2R knockout mice exposed to partial sci-
atic nerve injury with concurrent neuropathic pain-like be-
haviors (Racz et al. 2008b) also revealed increased bilateral
dorsal horn microglial activation compared to wildtype con-
trols. These results suggest that CB2Rs play a regulatory role
in microglial activation during peripheral neuropathic con-
ditions. However, we report that i.t. AM1241 does not in-
hibit dorsal spinal microglial activation, as assessed by Iba-1
staining, despite full behavioral reversal of CCI-induced al-
lodynia. Upregulation of Iba-1 is widely known to indicate
activemicroglia(Ohsawaetal.2000;Ibrahimetal.2010;Kraft
etal.2011).Thedifferencesinthedataresultsmaybethatthe
aminoalkylindole,AM1241,actsinadistinctlydifferentman-
nerthanotherCB2Ragonistcompounds,perhapsbyinhibit-
ing general spinal proinﬂammatory processes while leaving
microglialfunctionintact.Importantly,increasedexpression
ofmicroglialIba-1isindicativeofongoingmicroglialactivity,
but cannot distinguish anti-inﬂammatory versus proinﬂam-
matory phenotypes. Thus, it is possible that the increased
microglial Iba-1 reported here may be a consequence of in-
creased IL-10 and/or mitogen-activated protein phosphatase
production, which are negative regulators to several proin-
ﬂammatory MAPKs (Romero–Sandoval et al. 2009). This
notion is supported by a prior in vitro study that demon-
strated CB2R ligands enhance IL-10 release from immune
stimulated macrophages (Correa et al. 2005).
Intriguingly, microglia are an important additional
source of the endocannabinoid, 2-arachidonylglycerol (2-
AG) (Stella 2009). Endocannabinoids such as anandamide
(AEA) and 2-AG are produced and released from neurons
and microglia (Walter et al. 2003). Increased endocannabi-
noid ligand expression and activity in regions such as the
spinalcordarecharacterizedtoinhibitpain-likebehaviorsin
rats (Martin et al. 1999; Kinsey et al. 2010).
In contrast to persistent microglial activity, i.t. AM1241
reduced bilateral GFAP IR in spinal cord astrocytes and ro-
bustly suppressed satellite GFAP IR in the corresponding
DRGs. These results support that CB2Ra c t i v a t i o nr e v e r s e s
chronic bilateral allodynia, in part, by suppressing astrocyte
activation. In other studies using immunohistochemical ex-
aminationofastrocytesandmicroglia,itisnotablethatastro-
cyteend-feetfrequentlymakeintimatecontactwithmicroglia
(Choi et al. 2009; Martin et al. 2010), providing a potential
mechanism by which microglia, albeit activated but in an
anti-inﬂammatory manner, can inﬂuence astrocyte activa-
tion.
The enzyme, MAGL, has been identiﬁed on presynaptic
axon terminals in brain, suggesting it can terminate 2-AG
activity following ligand–receptor internalization in presy-
naptic neurons (Dinh et al. 2002; Gulyas et al. 2004). The
current report supports, but is not limited to, the presynap-
tic localization of MAGL because immunoﬂuorescent levels
were dramatically increased by neuropathy in the superﬁcial
dorsal horn where afferent nociceptive ﬁber terminals com-
municatetospinalcordpain-processingneurons.Thesedata
extend prior reports by showing a strong decrease in spinal
MAGLIRfollowingi.t.AM1241thatisconcurrentwithcom-
pletereversalofallodynia.Indeed,MAGLinhibitorsdecrease
allodynia in CCI-induced neuropathic mice (Kinsey et al.
2009), resulting in an increase in 2-AG accumulation that is
widely characterizedto produce analgesia (Sagar et al. 2009).
Microgliaalsorelease2-AG,andMAGLactivityhasbeende-
scribed in microglia (Muccioli et al. 2007). Together, these
data support that decreased MAGL IR may be a result of a
generalized decrease in proinﬂammatory factors following
AM1241 treatment.
Surprisingly, an unremarkable unilateral alteration of
FAAH was observedfollowing CCI-neuropathycomparedto
sham controls, and these levels remained unchanged follow-
ing i.t. AM1241 injection. As such, it is not clear from these
data whether FAAH plays an important role in chronic pain
produced by CCI-peripheral neuropathy, given these levels
remained unchanged during pain reversal. However, only a
single biochemical marker was used to ascertain FAAH ex-
pressionlevels.Further,activityofFAAHmaynotbereﬂected
initslevelsofexpression.Insupportofthispossibility ,reports
have demonstrated that blockade of FAAH actions results in
anti-allodynia in inﬂammatory pain models (Booker et al.
2011), or following peripheral nerve transection (Lever et al.
2009),orCCI(Kinseyetal.2009).Thus,virtuallyunchanged
spinal FAAH IR levels should be cautiously interpreted until
further assays verify FAAH expression and activity in mod-
els of peripheral neuropathy. Distinct from data in the cur-
rent report, increased FAAH IR was observed in large di-
ameter DRG neurons following sciatic nerve axotomy or L5
spinal nerve transection (Lever et al. 2009). However, animal
models of peripheral axotomy can result in different protein
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expression proﬁles in spinal cord and DRG compared to in-
tact damaged axons, as is the case with CCI. These observed
differencesarefrequentlyreportedindifferentanimalmodels
of pathological pain (DeLeo et al. 2007).
DRG satellite cells form a distinct sheath that completely
surround sensory neurons, and together with the neuron,
create a discrete morphological (Hanani 2005) and a func-
tionalunit(Takedaetal.2009).SatelliteDRGgliahavegained
increasing recognition for altering nociceptive transmission
by expressing and responding to several proinﬂammatory
cytokines including IL-1β (Takeda et al. 2008, 2009). In-
deed,IL-1β rapidlyactivatesnociceptivecellsinap38MAPK-
dependent manner (Binshtok et al. 2008). The current
report supports these reports, as increased expression of p-
p38MAPK and IL-1β, in addition to GFAP, were present in
the DRG of neuropathic animals. We demonstrate that ipsi-
lateralDRGIL-10expressionissigniﬁcantlydecreasedduring
CCI-induced chronic neuropathy. Conversely, i.t. treatment
withAM1241resultedingreaterp-p38MAPK,IL-1β,andIL-
10 IR levels that are similar to non-neuropathic control basal
values.NoIL-10,IL-1β,andp-p38MAPKIRchangesincon-
tralateral DRG were observed during CCI-induced chronic
allodynia, suggesting these immune signals in contralateral
DRGdonotplayasigniﬁcantroleinCCI-inducedcontralat-
eral allodynia.
Although AM1241s behavioral effects occur within a rel-
atively short therapeutic half-life (∼1.5 h), these data reveal
crucial ﬁndings that may support the development of longer
lasting, “next generation” CB2Ra g o n i s t st op r o d u c et h e r a -
peuticpaincontrol.Anadvantageofashorttherapeutichalf-
life is the capability to tightly regulate drug loading doses
and potential unwanted side effects. Oral formulations easily
allowforrepeateddosingatdiscreteintervals.Additionally,a
short half-life for i.t. efﬁcacy localized to the spinal cord may
be advantageous as it may remain localized to spinal canal,
avoiding potential global inhibition of important immune
function. Prior reports together with the data presented here
support that the actions of AM1241 are highly effective to
control pathological pain when delivered either peripherally
or by i.t. administration. Additionally, this report supports
that pathological pain states, which can include contralateral
allodynia (“mirror image” body part) is mediated by sig-
niﬁcant shifts in ipsilateral and contralateral pro- and anti-
inﬂammatory spinal cord cytokine milieu, as well as shifts
in p38MAPK and the endocannabinoiddegradative enzyme,
MAGL. The implication of these results is that compounds
capable of acting on cytokines in the CNS, can therapeu-
tically control clinically relevant centrally and peripherally
mediated pathological pain conditions.
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